Latest Europe News

Collins Foods posted record FY26 revenue and underlying profit, exited Taco Bell to focus on KFC growth, and outlined ambitious expansion plans in Germany and Australia.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.

Advance ZincTek posted an 11% rise in FY26 profit before tax to $2.247 million on 12.6% higher sales, driven by AI integration and US market strength. The company is set to enter residential battery manufacturing in FY27, leveraging its zinc oxide expertise.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

Pengana Global Private Credit Trust (ASX: PCX) reported a solid FY26 with an 8.8% cash distribution yield and stable credit quality despite fair value pressures from widening credit spreads.

ClearVue Technologies saw a 35% revenue decline to $161,000 and a $11 million net loss in FY2026, driven by a major operational overhaul and significant product certification efforts. Despite the financial setback, the company expanded into new markets and secured key commercial projects.

Orbital Corporation has broadened its customer base and product lineup, positioning itself to capture growth in defence and commercial UAV markets with $3.2 million in expected sales for Q1 FY2027.

AML3D Limited surged to a record $12.5 million revenue in FY26, delivering its first half-year EBITDA profit and locking in a $29 million order book driven by US Defence contracts and UK market entry.

Atomo Diagnostics lifted revenue 41% to AUD 5.33 million for FY26, cutting its loss by 29% to AUD 3.51 million, driven by HIV self-testing growth and a key US partnership. Leadership changes signal a strategic pivot as the company eyes global expansion.

IODM Limited’s FY26 results show solid revenue gains led by UK education, but losses persist with a net deficiency in equity raising going concern questions.

Vection Technologies (ASX:VR1) achieved a major earnings inflection in FY26 with adjusted EBITDA soaring 596% to $3.8 million and generating positive operating cash flow for the first time, underpinned by dual commercial platforms scaling rapidly.